AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02114346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02114346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride
Description: Patients with estimated glomerular filtration rate of less than 60 mL/min/1.73 m2 are hydrated with 0.9% sodium chloride for 2 hours, from 1 hour before (3 mL/kg/hour) to 1 hour after (1 mL/kg/hour) operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg/hour.
Study NCT02114346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: Patients with estimated glomerular filtration rate of less than 60 mL/min/1.73 m2 are hydrated with 0.9% sodium chloride for 2 hours, from 1 hour before (3 mL/kg/hour) to 1 hour after (1 mL/kg/hour) operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg/hour.
Study NCT00242424 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 2005-2006 trivalent inactivated influenza vaccine
Description: Children enrolled at 6-12 weeks to receive first dose, 0.25 ml of trivalent inactivated influenza vaccine, 2005-6 pediatric Fluzone formulation (sanofi pastuer), with concomitant routine pediatric vaccines. Second dose administered 4 weeks later.
Study NCT00242424 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2005-2006 trivalent inactivated influenza vaccine
Description: Children enrolled at 6-12 weeks to receive first dose, 0.25 ml of trivalent inactivated influenza vaccine, 2005-6 pediatric Fluzone formulation (sanofi pastuer), with concomitant routine pediatric vaccines. Second dose administered 4 weeks later.
Study NCT01088594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rosiglitazone/placebo/pioglitazone
Description: single oral dose of rosiglitazone 8mg + single oral dose of placebo + single oral dose of pioglitazone 45mg
Study NCT01088594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo/rosiglitazone/pioglitazone
Description: single oral dose of placebo + single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg
Study NCT01088594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo/rosiglitazone/pioglitazone
Description: single oral dose of placebo + single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg
Study NCT04351724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine or Hydroxychloroquine
Description: Hydroxychloroquine 200mg 2-0-2 on day 1 followed by 200mg 1-0-1, or Chloroquine 250mg 2-0-2, as available
Study NCT04351724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: Lopinavir/Ritonavir 200mg/50mg 2-0-2
Study NCT04351724 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best standard of care
Description: best standard of care
Study NCT04351724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: 2.5mg 2-0-2 or 10mg 1/2-0-1/2, as applicable
Study NCT04351724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thromboprophylaxis
Description: as local standard, most likely to be low molecular weight heparin
Study NCT04351724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: starting dose 4mg once daily, titrated to normotension
Study NCT04351724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-RAS blocking antihypertensives
Description: This excludes angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (AT-blockers, sartans) and includes alpha-receptor antagonists, calcium antagonists, amongst others
Study NCT04351724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: 200mg on day 1, thereafter 100mg for a total of 5-10 treatment days, according to local standards
Study NCT04351724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunercept 400mg
Description: asunercept 400mg once per week, up to 4 doses in total
Study NCT04351724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunercept 100mg
Description: asunercept 100mg once per week, up to 4 doses in total
Study NCT04351724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunercept 25mg
Description: asunercept 25mg once per week, up to 4 doses in total
Study NCT04351724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentaglobin
Description: 7ml/kg/day for 12h for 5 days
Study NCT02333019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Let's Talk About Sex
Description: Multimedia web site to build parental skills in communicating with their pre-adolescnet child sex and relationships, pregnancy prevention, and risk of sexually transmitted infections.
Study NCT02333019 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Websites; preventing teen pregnancy
Description: Two general web sites with information about preventing teen pregnancy
Study NCT02141139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAIDS (ketorolac and ibuprofen)
Study NCT03459638 — intervention group
Intervention type: OTHER
Intervention: Screening for DM, ASCVD, MetS and OSAS
Description: Finger stick analysis, questionnaires and clinical measurements
Study NCT03129360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam is an atypical anticonvulsant that is frequently used in children and adults due to its superior tolerability, ease of use and excellent safety profile.
Study NCT03129360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prepared in capsules to appear identical to levetiracetam.
Study NCT03171818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: Darbepoetin alfa (Aranesp, Amgen) 2 doses of 10 microgram/kg i.v.
Study NCT03171818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The placebo will consist of saline, containing 9.0 g of salt per liter (0.90%) i.v.
Study NCT04098861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost/Timolol
Description: Latanoprost/Timolol Fixed Combination
Study NCT03358134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: anti IL17 therapy (subcutaneous)
Study NCT03759106 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: home written exercise program
Description: exercises such as picking up objects, placing objects, frequently prescribed at discharge
Study NCT03759106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telerehabilitation/exergame system
Description: Video games using the Kinect camera that are carried out using the impaired arm and monitored by a therapist by videoconferencing
Study NCT00285168 — intervention group
Intervention type: BEHAVIORAL
Intervention: Bone Density Decision Aide
Description: Absolute 10-year Fracture Risk Report
Study NCT03739515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HSCP intervention
Description: A team of HSCPs (physiotherapist, occupational therapist, medical social worker) will provide comprehensive functional assessment to older patients
Study NCT03739515 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ED routine care
Description: ED staff including consultants and nurses will provide patients with routine ED medical care.
Study NCT01054625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: zalutumumab
Description: Zalutumumab is a clear to opalescent liquid. It is intended for intravenous infusion following dilution in sterile, pyrogen free, 0.9% NaCl. Patients will be treated at a specified dose of Zalutumumab over a period of 7 weeks. The dose will be 4mg/kg, 8mg/kg or 16mg/kg depending on when they enter the study. The study will begin with 6 patients on 4mg/kg, then 10 patients on 8mg/kg and lastly 10 patients on 16mg/kg.
Study NCT00231413 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV 16/18 L1 AS04
Description: 3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
Study NCT00231413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16/18/31/45 L1 AS04 Formulation 1
Description: 3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
Study NCT00231413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16/18/31/45 L1 AS04 Formulation 2
Description: 3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
Study NCT00231413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16/18/31/45 L1 AS04 Formulation 3
Description: 3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
Study NCT00231413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16/18/31/45 L1 AS04 Formulation 4
Description: 3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
Study NCT00231413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16/18/31/45 L1 AS04 Formulation 5
Description: 3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
Study NCT00231413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16/18/31/45 L1 AS04 Formulation 6
Description: 3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
Study NCT00565136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOPAS
Description: A mesh sling permanently implanted to increase pelvic floor support
Study NCT00119821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Reducing Diet
Description: Behavioral intervention
Study NCT00119821 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Moderate exercise implemented plus behavioral intervention.
Study NCT00119821 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smoking Cessation
Description: Nicotine Patch in dosages given based on number of cigarettes per day smoked. 21 mg patch, 14 mg patch, 7 mg patch for total of 6 weeks duration of therapy.~NRT gum is being provided to assist with relapse prevention. At the randomization visit the participant is given one (1) box of 2mg NRT gum, which consists of (110) pieces. The participant may request up to two (2) more boxes, for a maximum of three (3) boxes per participant.
Study NCT02640495 — intervention group
Intervention type: DRUG
Intervention: Intravenous Artesunate as part of standard medical practice
Description: Intravenous Artesunate 2.4 mg/kg
Study NCT02687087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visco-ease
Description: 19.6 mg/mL of LMS-611
Study NCT02687087 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological Saline
Study NCT01520025 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET MPI imaging with 18F-Fluorodeoxyglucose
Description: Exercise Stress Testing. All patients will undergo a symptom-limited exercise treadmill test using the Bruce protocol after a 24 hour high fat, low carbohydrate diet and an overnight fast. Persantine Stress Testing: Subjects who have undergone Persantine stress protocol for the PET or SPECT will follow the same protocol. A high fat, low carbohydrate diet for 24 hours and a 12 hour overnight fast will precede the study stress scan. Anti-anginal medications will be withheld on the morning of the exercise test.~18FDG (370 mBq) will be injected at either peak exercise or within 1 hour of peak.~Patients will be imaged 60 minutes after radiotracer injection in the supine position in a Discovery 690/VCTLYSO PET system (GE Healthcare, Milwaukee, Wisconsin)
Study NCT00632333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: URLC10, TTK, KOC1, VEGFR1, VEGFR2, cisplatin, fluorouracil
Description: Escalating dose of multiple peptides (URLC10, TTK, KOC1 VEGFR1, and VEGFR2) emulsified with Montanide ISA51 will be administered by subcutaneous injection on days 15, 22, 28 and 35 of treatment cycle. Doses of each peptide are planning 0.5mg, 1mg and 3mg/body. Chemotherapy plus radiation therapy will be done as follows: fluorouracil (400mg/m2) on day1-5 and 8-12, cisplatin (40mg/m2) on days 1 and 8, radiation (2Gy) on days 1-5, 8-12 and 15-19. Two cycles of combination of chemoradiation therapy and epitope peptide vaccine therapy will be done.
Study NCT01652664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% PQ ophthalmic solution
Study NCT01652664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol, 0.5% or 0.25% ophthalmic solution
Description: Patients 2 months to \< 3 years of age received 0.25%
Study NCT01652664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Vehicle
Description: Inactive ingredients used to maintain masking
Study NCT04444596 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Conjunctival swab and nasopharyngeal swab
Description: Both conjunctival swab and nasopharyngeal swab for SARS-COV 2 are conducted in patients with COVID-19.
Study NCT02062762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online-MBSR
Description: 8 week mindfulness based stress reduction online
Study NCT00003610 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: capsaicin
Study NCT00003610 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00003610 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00003610 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiation therapy
Study NCT02663843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel airway
Description: Fibreoptic intubation via i-gel airway device
Study NCT02663843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: air-Q airway
Description: Fibreoptic intubation via air-Q airway device
Study NCT02062762 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expressive Writing Online
Description: Online distributed expressive writing intervention as active control
Study NCT02103283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teprotumumab
Description: Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions
Study NCT05231434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water
Description: hydration with mineral water in 10 equal portions, administered at regular intervals from the 15th minute of exercise until the end of the recovery period.
Study NCT05231434 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic activity
Description: aerobic activity
Study NCT01668355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Aligned Care Team (PACT)
Description: An integrated healthcare model to coordinate and address physical health needs of people with serious mental illness. This specialized PACT medical home model is designed for individuals with serious mental illness.
Study NCT00935441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: case management with telemonitoring
Description: telephone contact with a case manager, home telemonitoring equipment for blood sugar and blood pressure, home HbA1c measurement
Study NCT00935441 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual case management
Description: telephone contact with a case manager
Study NCT00353106 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: 30-minute interviews of participating patients and their caregiver(s).
Study NCT05231434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic activity
Description: aerobic activity
Study NCT01068548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reminder
Description: computer based reminder to change patients from IV to oral antibiotics based on evidence based clinical practice guidelines
Study NCT04109092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7766
Description: E7766, solution, intravesically.
Study NCT03213821 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: protein intake
Description: For each participant, weighed food records of 3 consecutive days will be analyzed for estimation of calorie and macronutrient intake and dietary preferences. To make sure good compliance, diets will be developed regarding patient's dietary habits and preferences individually. High calorie (30-35 kcal/kg Ideal body weight) diets including 6-8 small meals will be formulated. Intervention group will receive high protein diet as recommended to preserve muscle mass (1.2-1.5 g/kg IBW). Comparison group will receive protein based on GFR to preserve renal function. For older adults (>65 years) protein content of diet will be as recommended by the international study group to review dietary protein needs with aging (PROT-AGE). In subjects with lower intake of protein, carbohydrate will be substituted. Both group will receive low fat diet.
Study NCT03213821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protein intake
Description: For each participant, weighed food records of 3 consecutive days will be analyzed for estimation of calorie and macronutrient intake and dietary preferences. To make sure good compliance, diets will be developed regarding patient's dietary habits and preferences individually. High calorie (30-35 kcal/kg Ideal body weight) diets including 6-8 small meals will be formulated. Intervention group will receive high protein diet as recommended to preserve muscle mass (1.2-1.5 g/kg IBW). Comparison group will receive protein based on GFR to preserve renal function. For older adults (>65 years) protein content of diet will be as recommended by the international study group to review dietary protein needs with aging (PROT-AGE). In subjects with lower intake of protein, carbohydrate will be substituted. Both group will receive low fat diet.
Study NCT02589782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Study NCT02589782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Study NCT02589782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Study NCT02589782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Study NCT02354729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral Economics
Description: Use financial incentives to promote epinephrine-carrying.
Study NCT00353106 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires that will take approximately 5 minutes to complete.
Study NCT01764399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care4U
Study NCT02166710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adductor canal femoral nerve block
Description: A 18 Gauge Tuohy needle will be inserted and its position will be confirmed using ultrasound guidance. Once the adequacy of the position is confirmed, the anesthesiologist will administer 15 mL of bupivacaine 0.25% with epinephrine in divided doses and examine the quality of its spread. A 20 Gauge polyamide catheter will be inserted at 2 cm in the space. The needle will then be withdrawn and the catheter will be fixed in place. Three mL of the same mixture of local anesthetics will be administered through the catheter and the anesthesiologist will observe the quality of its distribution. Bupivacaine 0.125% will be administered through the catheter using an infusion pump for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
Study NCT02166710 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Simulated nerve blockade
Description: The insertion of the Tuohy needle and the injection of 15 mL of bupivacaine 0.25% with epinephrine will be simulated. The insertion of the polyamide catheter, the withdrawal of the needle and the injection of local anesthetics through the catheter will also be simulated. The infusion of bupivacaine 0.125% will also be simulated for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
Study NCT02589782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Study NCT02589782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
Study NCT03697668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: triple combination for the treatment of malaria
Study NCT03697668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine
Description: standard malaria treatment
Study NCT01865279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Ascending single doses - 5 dose levels. Escalation to next dose level will be performed following evaluation of safety data.
Study NCT01865279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Ascending single doses - 5 dose levels